Navigation Links
MultiCell Technologies Launches New Web Site

WOONSOCKET, R.I., July 30 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has launched a new website with a fresh new look and updated information about discovery technology platforms and lead drug candidates. It also provides information to answer investors' most common questions.

"The new website is designed to inform our shareholders, scientists and the public about the Company's proprietary therapeutic pipeline which could fill critical unmet medical needs," stated W. Gerald Newmin, Chairman and CEO of MultiCell.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for treatment of neurological disorders, hepatic disease and cancer.

MultiCell's therapeutic development platform relies on patented techniques to: (i) isolate, characterize and differentiate stem cells from the human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin treatment, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

MultiCell's drug candidates are in various stages of discovery optimization, and preclinical and clinical development:

  • MCT-125 is a Phase 2 therapeutic candidate for treatment of fatigue in MS patients, which has demonstrated efficacy in a 138-patient Phase IIa clinical trial.
  • MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
  • MCT-475 is a discovery stage antibody therapeutic candidate for use in combination with dsRNA for the treatment of solid tumor cancers.
  • MCT-485 is a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

For more information about MultiCell Technologies, please visit

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs.  MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2009, and quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
2. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
3. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
4. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
5. Reportlinker Adds Wireless Medical Technologies 2007-2010
6. RF Technologies® Announces Version 7 Software for Safe Place® Security Solutions
7. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
8. RF Technologies(R) Installs Updated Version of its Safe Place(R) Solution for Infant Security at Sutter Tracy Community Hospital
9. Wound Management Technologies, Inc. Expands Distribution Channel into Five Central American Countries
10. China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
11. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
Post Your Comments:
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... it will be sharing additional findings from the multicenter ... Therapeutics (TCT) meeting in San Francisco ... Device , announced that it will be sharing additional ... community at the Trans-Catheter Therapeutics (TCT) meeting in ...
(Date:10/13/2015)... , Oct. 13, 2015  The spine division of ... in musculoskeletal healthcare, will showcase its portfolio of innovative ... Society (NASS) annual meeting, October 14-17, 2015, in ... host two clinical events: "Supplemental MIS Fixation ... Wednesday, October 14 12:30 – 1 p.m. --> ...
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Sir Grout of Greater Boston donated an expansive, seven room ... McDonald House Charities® (RMHC®). This donation was made in an effort to give back ... its inception. , “We believe strongly in the Ronald McDonald House Charities, and they ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of its ... with, participate in local fitness & sporting events, and stay motivated. Users ... medical costs drive us to get more serious about fitness and wellness, individuals are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):